Each cycle last 21-days. All subjects will receive abraxane via IV on Day 1 and Day 8 of each cycle. Subjects will either receive pembrolizumab (IV) on Day 1 of each cycle. Subjects may continue to receive the study regimen until they experience disease progression or unacceptable toxicity.